Royal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension
Condition(s) studied
Investigational drug(s) / intervention(s)
Royal Jelly: Participants will receive 2 capsules per day, providing the dosage of 300mg of royal jelly for 2 months (8 weeks).
Placebo: The placebo group will receive 2 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.
Study summary
The study aims to evaluate the effect of the royal jelly on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.
Eligibility
Primary outcome measure(s)
- Change of inflammatory transcripton factor — Baseline and 8 weeks
Assessment of NFkB expression levels in blood samples collected at baseline and after 8 weeks of supplementation.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Denise Mafra | Rio de Janeiro | Rio de Janeiro | Recruiting |
More Universidade Federal Fluminense trials in Brazil
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06917131 on ClinicalTrials.gov ↗ ← All trials in Brazil